Precipio

Historical price data

Precipio is a mission-driven cancer diagnostics company tackling the critical problem of diagnostic error, which it cites affects 1 in 4 blood cancer patients. The company has built a dual-pronged business model: a high-complexity clinical laboratory providing expert-integrated diagnostic services, and a product division commercializing proprietary test kits (e.g., HemeScreen panels, IV-Cell media) born from its lab insights. Its strategy leverages its specialized hematopathology expertise and internally developed technologies to drive diagnostic accuracy, improve lab economics, and capture market share in the growing precision oncology diagnostics space.

An integrated platform combining the proprietary Omnia diagnostic methodology, expert hematopathology services, and a suite of internally developed products (HemeScreen PCR panels, IV-Cell culture media, Rev-CI enrichment tech) to maximize accuracy in cancer diagnosis.

Precipio faces competition from large national reference labs (Quest, LabCorp) and specialized oncology labs (NeoGenomics) in services, and from major IVD manufacturers (Abbott, Roche) in products. It differentiates through its exclusive hematopathology focus, integrated expert model (Omnia), and proprietary technologies designed to address specific diagnostic accuracy gaps.